Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $58.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. Guggenheim increased their price target on Celldex Therapeutics from $72.00 to $90.00 and gave the company a buy rating in a research note on Tuesday, February 27th. Wolfe Research initiated coverage on Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an outperform rating and a $51.00 price target on the stock. HC Wainwright restated a buy rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Monday, June 3rd. Finally, Cantor Fitzgerald restated an overweight rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Friday, March 22nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $62.17.

Celldex Therapeutics Trading Down 0.7 %

NASDAQ CLDX opened at $34.66 on Tuesday. The company has a market cap of $2.28 billion, a PE ratio of -12.16 and a beta of 1.48. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month high of $53.18. The stock has a 50 day moving average of $37.54 and a 200-day moving average of $39.06.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.11. The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. As a group, sell-side analysts predict that Celldex Therapeutics will post -2.32 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Elizabeth Crowley sold 38,597 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $33.64, for a total value of $1,298,403.08. Following the transaction, the vice president now owns 9,074 shares in the company, valued at $305,249.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Samuel Bates Martin sold 35,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the transaction, the chief financial officer now owns 25,128 shares in the company, valued at $855,608.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Elizabeth Crowley sold 38,597 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the transaction, the vice president now owns 9,074 shares in the company, valued at approximately $305,249.36. The disclosure for this sale can be found here. Insiders have sold 266,332 shares of company stock worth $9,155,821 in the last 90 days. Company insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP increased its position in shares of Celldex Therapeutics by 19.2% in the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after purchasing an additional 1,044,728 shares during the period. Vanguard Group Inc. boosted its stake in Celldex Therapeutics by 19.8% in the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after buying an additional 604,251 shares in the last quarter. Eventide Asset Management LLC boosted its stake in Celldex Therapeutics by 126.9% in the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after buying an additional 2,030,013 shares in the last quarter. Kynam Capital Management LP boosted its stake in Celldex Therapeutics by 23.1% in the third quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock valued at $88,064,000 after buying an additional 600,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after buying an additional 2,664,915 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.